(Q54631878)

1 June 2018

title

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. (English)

1 reference

1 June 2018

1 reference

acute myeloid leukemia

1 reference

childhood acute myeloid leukemia

inferred from title

1 reference

2

1 reference

1 June 2018

Mar Tormo

13

1 reference

1 June 2018

Lourdes Florensa

14

1 reference

1 June 2018

Josep Nomdedeu

23

1 reference

1 June 2018

author name string

G Perea

1

1 reference

1 June 2018

A Aventín

3

1 reference

1 June 2018

A Domingo

4

1 reference

1 June 2018

N Villamor

5

1 reference

1 June 2018

M Paz Queipo de Llano

6

1 reference

1 June 2018

A Llorente

7

1 reference

1 June 2018

J Juncà

8

1 reference

1 June 2018

C Palacios

9

1 reference

1 June 2018

C Fernández

10

1 reference

1 June 2018

M Gallart

11

1 reference

1 June 2018

L Font

12

1 reference

1 June 2018

J Bargay

15

1 reference

1 June 2018

J M Martí

16

1 reference

1 June 2018

P Vivancos

17

1 reference

1 June 2018

P Torres

18

1 reference

1 June 2018

J J Berlanga

19

1 reference

1 June 2018

I Badell

20

1 reference

1 June 2018

S Brunet

21

1 reference

1 June 2018

J Sierra

22

1 reference

1 June 2018

Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel

24

1 reference

1 June 2018

publication date

1 January 2006

1 reference

1 June 2018

published in

Leukemia

1 reference

1 June 2018

volume

20

1 reference

1 June 2018

issue

1

1 reference

1 June 2018

page(s)

87-94

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404015

exact match

0 references

cites work

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Determination of minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Typical CBFbeta/MYH11 fusion due to insertion of the 3'-MYH11 gene into 16q22 in acute monocytic leukemia with normal chromosomes 16 and trisomies 8 and 22

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404015

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404015

1 reference

1 June 2018

1 reference

1 June 2018